Doctor Marco Gnesi
AstraZeneca, Milan (Italy)
Follow
Contributor content
Journal
Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)
28 October 2024
